From: Case-control Indian buffet process identifies biomarkers of response to Codrituzumab
Continuous Variables
Effect Size
p-value
%Necrotic
2.73
1.86e-04
CD3/CD16 necrotic
2.63
2.85e-04
%Viable
−0.86
CD3/CD16 viable
−0.85